Anne is a seasoned healthcare executive and corporate director with more than 25 years of experience across multiple companies and geographies. She has a proven track record of building and leading high-performance teams to successfully commercialize pharmaceuticals, consumer products and medical devices. Anne attributes her career success to being an authentic, courageous and agile leader who establishes high performance cultures that enable teams to deliver exceptional results. She has been recognized in the pharmaceutical industry by Fierce Pharma as one of the top 25 Most Influential People in BioPharma in 2012 and 2013, and in 2014 as one of the top 25 Most Influential Women in BioPharma. She is active in the North Carolina community mentoring women and men in pursuit of STEM careers and leadership positions. She is a member of Women Corporate Directors, Healthcare Businesswomen’s Association, International Women’s Forum and OnBoardNC.
Anne started her healthcare career with The Upjohn Company selling pharmaceuticals to treat diabetes and arthritis. She subsequently transitioned to GlaxoSmithKline PLC (GSK: NYSE) where she rose in the commercial ranks to become a Senior Vice President for the Cardiovascular, Metabolic, and Urology franchises in 2009. Anne joined Sanofi SA (SAN-FR: Euronext Paris) in 2011 as the President of the North America Region where she led more than 5000 commercial and medical employees to deliver ~$10B in net sales equaling > 30% of the net sales and >50% of the profit for Sanofi globally. Anne served as the CEO and President of Synta Pharmaceuticals, Inc. (SNTA: NASDAQ) traded company in 2014 and 2015. She joined Bausch Health Company, Inc. (BHC: NYSE) as an Executive Vice President and Company Group Chairman for the Branded Pharmaceuticals segment in mid 2015 where she led the successful integration of Salix Pharmaceuticals and Dendreon, built the U.S. Pharmaceutical Commercial Operations and Market Access team, launched Xifaxan for irritable bowel syndrome and led the Western European Region.
More recently, Anne served as the CEO and President of KNOW Bio, LLC, a privately held life science company, and its subsidiary, Novoclem Therapeutics, Inc., now Vast Therapeutics, from February 2017 until April 2018. She is currently an independent director on the board of Cree (CREE: NASDAQ), a LED and semiconductor company, Mallinckrodt (MKN: NYSE), a specialty pharmaceutical company, Vectura (VEC-GB: London Exchange), a pharmaceutical and medical device company, and a Trustee for the University of North Alabama.
Anne holds a Bachelor of Science degree in chemistry from the University of North Alabama.